MedTrace Logo

Guiding Evidence Based Therapy Using Biomarker Intensified Treatment

NCT01685840 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 894

Last updated 2017-12-12

Study results available
· View outcomes & findings →

Summary

The primary objective is to determine the efficacy of a strategy of biomarker-guided therapy compared with usual care in high risk patients with left ventricular systolic dysfunction.

Conditions

Interventions

OTHER

Usual Care

Usual Care

DEVICE

Biomarker-guided care NT-proBNP

Device: NT-proBNP

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • Michael Felker, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2016-09-20
Completion
2016-09-20

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01685840 on ClinicalTrials.gov